NZ598247A - Compositions and methods for treating parkinson’s disease - Google Patents

Compositions and methods for treating parkinson’s disease

Info

Publication number
NZ598247A
NZ598247A NZ598247A NZ59824710A NZ598247A NZ 598247 A NZ598247 A NZ 598247A NZ 598247 A NZ598247 A NZ 598247A NZ 59824710 A NZ59824710 A NZ 59824710A NZ 598247 A NZ598247 A NZ 598247A
Authority
NZ
New Zealand
Prior art keywords
disease
methods
compositions
parkinson
treating parkinson
Prior art date
Application number
NZ598247A
Other languages
English (en)
Inventor
Philip Seeman
Original Assignee
Clera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clera Inc filed Critical Clera Inc
Publication of NZ598247A publication Critical patent/NZ598247A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ598247A 2009-07-31 2010-07-30 Compositions and methods for treating parkinson’s disease NZ598247A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23026409P 2009-07-31 2009-07-31
PCT/CA2010/001185 WO2011011886A1 (en) 2009-07-31 2010-07-30 Compositions and methods for treating parkinson's disease

Publications (1)

Publication Number Publication Date
NZ598247A true NZ598247A (en) 2014-01-31

Family

ID=43528672

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598247A NZ598247A (en) 2009-07-31 2010-07-30 Compositions and methods for treating parkinson’s disease

Country Status (12)

Country Link
US (1) US9192605B2 (OSRAM)
EP (1) EP2459194A4 (OSRAM)
JP (1) JP5756105B2 (OSRAM)
KR (1) KR20120103557A (OSRAM)
CN (1) CN102548555A (OSRAM)
AU (1) AU2010278645A1 (OSRAM)
BR (1) BR112012008193A2 (OSRAM)
CA (1) CA2769149A1 (OSRAM)
IL (1) IL217149A0 (OSRAM)
MX (1) MX2012001290A (OSRAM)
NZ (1) NZ598247A (OSRAM)
WO (1) WO2011011886A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3178035A1 (en) * 2012-12-24 2014-07-03 Neurogastrx, Inc. Methods for treating gi tract disorders
JP6371716B2 (ja) * 2014-04-01 2018-08-08 東京エレクトロン株式会社 基板液処理装置及び基板液処理方法並びに基板液処理プログラムを記録したコンピュータ読み取り可能な記録媒体
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
CN114601928B (zh) * 2022-04-02 2023-03-17 首都医科大学 一种钙超载介导神经元死亡的标志物及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1219667B (it) * 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
RU2057529C1 (ru) * 1994-05-30 1996-04-10 Алексей Михайлович Коршунов Способ лечения синдрома паркинсонизма
US20010056101A1 (en) * 1998-06-29 2001-12-27 Carol A. Tamminga Use of dopamine receptor antagonists in combination with partial dopamine agonist to prevent tolerance in treating nervous disorders related to dopamine dysfunction
DE10111486A1 (de) * 2001-03-09 2002-10-02 Ralph R Dawirs Verwendung einer oder mehrerer neuroaktiver Substanzen zur Behandlung der Parkinsonschen Krankheit
JP2006502234A (ja) 2002-09-17 2006-01-19 モタック・ニューロサイエンス・リミテッド ジスキネジーの治療
CA2501781A1 (en) 2002-10-22 2004-05-06 Drugabuse Sciences S.A.S. Treatment of cognitive impairment using a selective dopamine d1 receptor agonist
EP1812081A1 (en) 2004-11-03 2007-08-01 Clera Inc. Method to detect dopamine receptors in the functional d2high state
US8791138B2 (en) 2008-02-05 2014-07-29 Clera Inc. Compositions and methods for alleviating depression or improving cognition

Also Published As

Publication number Publication date
IL217149A0 (en) 2012-02-29
KR20120103557A (ko) 2012-09-19
EP2459194A4 (en) 2012-12-19
US9192605B2 (en) 2015-11-24
EP2459194A1 (en) 2012-06-06
JP5756105B2 (ja) 2015-07-29
CN102548555A (zh) 2012-07-04
JP2013500943A (ja) 2013-01-10
US20120115910A1 (en) 2012-05-10
BR112012008193A2 (pt) 2016-03-01
AU2010278645A1 (en) 2012-03-08
WO2011011886A1 (en) 2011-02-03
CA2769149A1 (en) 2011-02-03
MX2012001290A (es) 2012-06-12

Similar Documents

Publication Publication Date Title
EA201071291A3 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
MX2011010782A (es) Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.
IL193080A0 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
ATE469895T1 (de) Cgrp-rezeptorantagonisten
IN2012DN02735A (OSRAM)
IN2012DN02730A (OSRAM)
IN2012DN00754A (OSRAM)
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
MX2020012868A (es) Metodos y composiciones para trastornos del sue?o y otros trastornos.
MX350761B (es) Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa.
EP2477625A4 (en) PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS COMPRISING PLECKSTRINE HOMOLOGY DOMAIN INHIBITORS AND METHODS OF USE
EP2365815A4 (en) EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER
PH12012500554A1 (en) Use of nicotinic acetylcholine receptor alpha 7 activators
IL222695A0 (en) Methods, compositions, and kits for the treatment of matrix mineralization disorders
PL2985032T3 (pl) Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
EP2285363A4 (en) ALPHA-ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP2323641A4 (en) NYASOL AND ANALOGUE THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR-BETA-MEDIATED ILLNESSES
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
IL193479A0 (en) Modulators of muscarinic receptors
UA102857C2 (en) Quinuclidine carbonate derivatives and use thereof
IL196672A0 (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
EP2257543A4 (en) MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, PROCESSING METHODS AND PREPARATION METHODS THEREOF
HRP20180531T1 (hr) Antagonisti serotoninskog 5-ht3 receptora za uporabu u liječenju površina vestibularnih lezija
NZ598247A (en) Compositions and methods for treating parkinson’s disease

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 JUL 2017 BY DAVIES COLLISON CAVE

Effective date: 20140502

LAPS Patent lapsed